Impact Biomedical (IBO) EBT Margin (2022 - 2026)
Impact Biomedical's (IBO) quarterly EBT Margin came in at 32628.57% in Q1 2026, down 298.18% on a QoQ basis from 8194.44% in Q3 2025.
Impact Biomedical (IBO) EBT Margin (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 3 years of EBT Margin data on file, last reported at 32628.57% in Q1 2026.
- Quarterly EBT Margin changed N/A year-over-year to 32628.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 60590.62% (changed N/A YoY) and the FY2022 annual result came in at 15752.0%, changed N/A from the prior year.
- EBT Margin eased to 32628.57% in Q1 2026, from 8194.44% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1598.0% in Q2 2022 to a low of 205028.57% in Q2 2025.
- A 3-year average of 61862.4% and a median of 20411.51% in 2025 frame the typical range for EBT Margin.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | -23,333.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23,333.33% |
| Mar 31, 2026 | -32,628.57% |
| Sep 30, 2025 | -8,194.44% |
| Jun 30, 2025 | -205,028.57% |
| Jun 30, 2022 | -1,598.00% |